Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Innate Pharma SA ( (FR:IPH) ) has shared an announcement.
On December 11, 2025, Innate Pharma released its financial calendar for 2026, detailing key dates for financial disclosures and shareholder meetings. This announcement provides stakeholders with a clear timeline for financial reporting, potentially impacting investor relations and market expectations.
The most recent analyst rating on (FR:IPH) stock is a Hold with a EUR1.50 price target. To see the full list of analyst forecasts on Innate Pharma SA stock, see the FR:IPH Stock Forecast page.
More about Innate Pharma SA
Innate Pharma S.A. is a global biotechnology company focused on developing immunotherapies for cancer patients. The company specializes in antibody-engineering and innovative target identification to create next-generation antibody therapeutics. Innate Pharma collaborates with major biopharmaceutical companies like Sanofi and AstraZeneca and is headquartered in Marseille, France, with a US office in Rockville, MD.
Average Trading Volume: 279,957
Technical Sentiment Signal: Strong Sell
Current Market Cap: €151.5M
See more data about IPH stock on TipRanks’ Stock Analysis page.